World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
59
Citations
11078
World Ranking
12682
National Ranking
434

Overview

Matthew C. Coffey is affiliated with Oncolytics Biotech in Canada and has contributed extensively to research in biochemistry, genetics, molecular biology, and medicine. Their work spans several subfields including oncology, genetics, biotechnology, molecular biology, and pathology and forensic medicine.

The scientist's research focuses primarily on virus-based gene therapy, CAR-T cell therapy, cancer research and treatments, colorectal cancer studies, lymphoma diagnosis and treatment, cancer immunotherapy and biomarkers, and RNA interference and gene delivery.

Notable recent publications include:

  • Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer (2020) in Molecular Cancer Therapeutics
  • BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab. (2023) in Journal of Clinical Oncology
  • Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma. (2021) in Journal of Clinical Oncology
  • 41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1) (2020) in Annals of Oncology
  • 619P Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study (2023) in Annals of Oncology

Frequent collaborators include Houra Loghmani, Grey Wilkinson, Richard Trauger, Thomas C. Heineman, and Devalingam Mahalingam.

The scientist's articles are primarily published in Journal of Clinical Oncology, Annals of Oncology, and Molecular Cancer Therapeutics.

Best Publications

  • Reovirus Therapy of Tumors with Activated Ras Pathway

    Matthew C. Coffey;James E. Strong;Peter A. Forsyth;Patrick W. K. Lee

  • The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

    James E. Strong;Matthew C. Coffey;Damu Tang;Pauline Sabinin

  • Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

    Adel Samson;Karen J. Scott;David Taggart;Emma J. West

  • A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

    Peter Forsyth;Gloria Roldán;Gloria Roldán;David George;Carla Wallace

  • A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

    Laura Vidal;Hardev S. Pandha;Timothy A. Yap;Christine L. White

  • Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

    Fiona Errington;Lynette Steele;Robin Prestwich;Kevin J. Harrington

  • Reovirus Oncolysis of Human Breast Cancer

    Kara L. Norman;Matthew C. Coffey;Kensuke Hirasawa;Douglas J. Demetrick

  • Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

    Robert A. Adair;Victoria Roulstone;Karen J. Scott;Ruth Morgan

  • Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

    Jian Qiao;Hongxun Wang;Timothy Kottke;Christine White

  • Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

    C L White;K R Twigger;L Vidal;L Vidal;J S De Bono

  • Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice

    Kensuke Hirasawa;Sandra G. Nishikawa;Kara L. Norman;Matthew C. Coffey

  • Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

    Eleni Karapanagiotou;Victoria Roulstone;Katie Twigger;Mercel Ball

  • Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.

    Evanthia Galanis;Svetomir N Markovic;Vera J Suman;Gerard J Nuovo

  • Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

    Karishma Rajani;Christopher Parrish;Timothy Kottke;Jill Thompson

  • Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

    Radharani Gollamudi;Mohammad H. Ghalib;Kavita K. Desai;Imran Chaudhary

  • Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

    Kimberly P Kicielinski;E Antonio Chiocca;John S Yu;George M Gill

  • Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

    E J Ilett;R J Prestwich;T Kottke;F Errington

  • REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

    Charles Comins;James Spicer;Andrew Protheroe;Victoria Roulstone

  • A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

    Martijn P. Lolkema;Hendrik-Tobias Arkenau;Kevin Harrington;Patricia Roxburgh

  • Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

    Kevin J. Harrington;Eleni M. Karapanagiotou;Victoria Roulstone;Katie R. Twigger

Frequent Co-Authors

Alan Melcher
Alan Melcher Institute of Cancer Research
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Richard G. Vile
Richard G. Vile Mayo Clinic
Peter Selby
Peter Selby University of Leeds
Gerard J. Nuovo
Gerard J. Nuovo The Ohio State University
Patrick W.K. Lee
Patrick W.K. Lee University of Calgary
Timothy Kottke
Timothy Kottke Mayo Clinic
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
David E. Cohn
David E. Cohn The Ohio State University
Christopher M. Nutting
Christopher M. Nutting Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology and Biochemistry in the USA opens up diverse career prospects, many of which are becoming increasingly accessible through online education. If you're considering advancing your qualifications, online degree programs offer flexible options suited for busy professionals and recent graduates alike.

For students interested in healthcare leadership, a phd in healthcare administration online can build skills in management and policy, leading to roles in hospitals, clinics, and public health organizations. Aspiring pharmacists may explore pharmd online programs, which combine foundational bioscience with practical, hands-on learning for careers in pharmacy and pharmaceutical research.

Some students prefer specialized clinical paths and can benefit from online dnp programs that remove traditional in-person clinical requirements. For those interested in sports health or fitness, an accredited sports science degree online provides expertise in physiology and athletic performance.

These online programs allow you to tailor your education to your career goals without relocating, making advanced study in Biology and related fields more accessible than ever.

Best Scientists Citing Matthew C. Coffey

Trending Scientists